Terbutaline

Terbutaline

SCHEMBL27361880

CC(C)(C)NCC(O)c1cc(O)cc(O)c1.CC(C)C(=O)O.CC(C)C(=O)O

nearest known ligand 0.79

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB2

The experimentally established mechanism targets of Terbutaline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 known ✓ P07550 6/20 0.79
LMNA P02545 5/20 0.79
HIF1A Q16665 4/20 0.79
TSHR P16473 4/20 0.79
KMT2A Q03164 3/20 0.79
CASP7 P55210 2/20 0.79
CYP3A4 P08684 1/20 0.79
CYP2C9 P11712 1/20 0.79
MEN1 O00255 2/20 0.73
BLM P54132 2/20 0.73
KDM4E B2RXH2 1/20 0.73
CASP1 P29466 1/20 0.73
SMN1; SMN2 Q16637 1/20 0.73
ADRA1A P35348 2/20 0.53
CYP2D6 P10635 3/20 0.50
ADRB1 P08588 2/20 0.50
CYP1A2 P05177 1/20 0.50
NFKB1 P19838 1/20 0.50
BCHE P06276 1/20 0.50
ACHE P22303 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Terbutaline SCHEMBL28876660 0.91 LMNA (0.79) ADRB2LMNAHIF1ATSHRKMT2A
Terbutaline SCHEMBL16553265 0.89 LMNA (0.81) ADRB2LMNAHIF1ATSHRKMT2A
Terbutaline SCHEMBL41869 0.89 LMNA (1.00) ADRB2LMNAHIF1ATSHRKMT2A
Terbutaline SCHEMBL13327959 0.89 LMNA (1.00) ADRB2LMNAHIF1ATSHRKMT2A
Terbutaline SCHEMBL4391 0.89 LMNA (1.00) ADRB2LMNAHIF1ATSHRKMT2A
Terbutaline SCHEMBL404480 0.87 ADRB2 (0.96) ADRB2LMNAHIF1ATSHRKMT2A
Terbutaline SCHEMBL11703058 0.87 ADRB2 (0.96) ADRB2LMNAHIF1ATSHRKMT2A
Terbutaline SCHEMBL5530880 0.85 LMNA (0.89) ADRB2LMNAHIF1ATSHRKMT2A
Terbutaline SCHEMBL4902064 0.85 LMNA (0.94) ADRB2LMNAHIF1ATSHRKMT2A
Terbutaline SCHEMBL9666580 0.85 LMNA (0.94) ADRB2LMNAHIF1ATSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102512676-A Methods of using a thiazole derivative OTSUKA PHARMA CO LTD 2012-06-27 CN claimed
CN-101472570-A Methods of using thiazole derivatives OTSUKA PHARMA CO LTD (JP) 2009-07-01 CN claimed
CN-1839833-A Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics BOEHRINGER INGELHEIM PHARMA (DE) 2006-10-04 CN claimed
CN-1688308-A Inhalation medicaments containing a novel anticholinesterase drug in conjunction with corticosteroids and betamimetic drugs BOEHRINGER INGELHEIM PHARMA (DE) 2005-10-26 CN claimed
CN-1120841-C Medicine composition and use thereof BOEHRINGER INGELHEIM KG (DE) 2003-09-10 CN claimed
CN-1350465-A Novel pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics BOEHRINGER INGELHEIM PHARMA (DE) 2002-05-22 CN claimed
CN-1191535-A Novel pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM KG (DE) 1998-08-26 CN claimed
CN-102892765-B Cyclohexylamine derivatives having beta 2 adrenergic agonist and M3 muscarinic antagonist activity ALMIRALL SA 2015-04-29 CN disclosed
CN-102892765-A Novel cyclohexylamine derivatives having beta 2 adrenergic agonist and M3 muscarinic antagonist activity ALMIRALL SA 2013-01-23 CN disclosed
CN-102512676-A Methods of using a thiazole derivative OTSUKA PHARMA CO LTD 2012-06-27 CN disclosed
CN-101472570-A Methods of using thiazole derivatives OTSUKA PHARMA CO LTD (JP) 2009-07-01 CN disclosed
CN-101296701-A A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (COPD) and asthma ASTRAZENECA AB (SE) 2008-10-29 CN disclosed
CN-101296698-A Combination of compounds for the treatment of respiratory diseases, in particular Chronic Obstructive Pulmonary Disease (COPD) and asthma ASTRAZENECA AB (SE) 2008-10-29 CN disclosed
CN-1085525-C Air pressed package using polyoxyethylene glyceryl oleate ASTM PHARMACEUTICAL CO LTD (DE) 2002-05-29 CN disclosed
CN-1350465-A Novel pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics BOEHRINGER INGELHEIM PHARMA (DE) 2002-05-22 CN disclosed
CN-1069191-C Compressed air packaging using polyoxyethylene glyceryl oleate ASTA MEDICA AG (DE) 2001-08-08 CN disclosed
CN-1306420-A Methods for treating capules and dry powdered pharmaceutical formulations BOEHRINGER INGELHEIM PHARMA (US) 2001-08-01 CN disclosed
CN-1259342-A Air pressed package using polyoxyethylene glyceryl oleate ASTA PHARMACEUTICAL CO LTD (DE) 2000-07-12 CN disclosed
CN-1259343-A Air pressed package using polyoxyethylene glyceryl oleate ASTA PHARMACEUTICAL CO LTD (DE) 2000-07-12 CN disclosed
CN-1080846-A Compressed air packaging using polyoxyethylene glyceryl oleate ASTA MEDICA AG (DE) 1994-01-19 CN disclosed